Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634263 | 0.94 | GRM5 (0.61) | GRM5MAPTCASRACP1KDM4E | |
| SCHEMBL3633806 | 0.90 | GRM5 (0.58) | GRM5MAPTCASRACP1KDM4E | |
| SCHEMBL3635985 | 0.89 | GRM5 (0.59) | GRM5MAPTS1PR1CASRKDM4E | |
| SCHEMBL3634276 | 0.88 | GRM5 (0.79) | GRM5MAPTCASRKDM4ELMNA | |
| SCHEMBL3632286 | 0.86 | GRM5 (0.82) | GRM5MAPTS1PR1 | |
| SCHEMBL3629201 | 0.82 | GRM5 (0.60) | GRM5MAPTS1PR1 | |
| SCHEMBL3634721 | 0.82 | GRM5 (0.59) | GRM5MAPTCASRKDM4EALDH1A1 | |
| SCHEMBL3632235 | 0.82 | GRM5 (0.62) | GRM5MAPTS1PR1ALDH1A1 | |
| SCHEMBL3633369 | 0.79 | GRM5 (0.55) | GRM5MAPTCASRKDM4EALDH1A1 | |
| SCHEMBL3633601 | 0.79 | KDM4E (0.58) | GRM5MAPTCASRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | GRM5 4545/4885MAPT 995/4885S1PR1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.